Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2567511 | 0.85 | IMPDH2 (0.33) | SMN1; SMN2 | |
| SCHEMBL6888914 | 0.80 | TSHR (0.45) | ESR1TSHRALDH1A1RECQLTDP1 | |
| SCHEMBL7862999 | 0.74 | SMN1; SMN2 (0.42) | ESR1PKMSMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL8111635 | 0.74 | PKM (0.38) | ESR1PKMSMN1; SMN2MTORRAB9A | |
| SCHEMBL29926635 | 0.74 | SMN1; SMN2 (0.42) | ESR1PKMSMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL10391657 | 0.73 | ITGB1 (0.32) | SMN1; SMN2TSHR | |
| SCHEMBL27510709 | 0.72 | ESR1 (0.38) | ESR1PKMSMN1; SMN2TSHRRECQL | |
| SCHEMBL22129210 | 0.72 | TSHR (0.38) | ESR1SMN1; SMN2TSHRALDH1A1TDP1 | |
| SCHEMBL28110591 | 0.71 | ESR1 (0.33) | ESR1SMN1; SMN2MTORRAB9ATSHR | |
| SCHEMBL23169065 | 0.71 | TSHR (0.53) | ESR1PKMSMN1; SMN2TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244318-A1 | Process for the Preparation of Levofloxacin Hemihydrate | RAO DAVULURI R | 2007-10-18 | — | — | US | claimed |
| EP-1809637-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LEVOFLOXACIN HEMIHYDRATE | Neuland Laboratories Ltd (IN) | 2007-07-25 | — | — | EP | claimed |
| WO-2006048889-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LEVOFLOXACIN HEMIHYDRATE | NEULAND LABORATORIES LTD. (IN) | 2006-05-11 | — | — | WO | claimed |
| US-20070244318-A1 | Process for the Preparation of Levofloxacin Hemihydrate | RAO DAVULURI R | 2007-10-18 | — | — | US | disclosed |
| EP-1809637-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LEVOFLOXACIN HEMIHYDRATE | Neuland Laboratories Ltd (IN) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006048889-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LEVOFLOXACIN HEMIHYDRATE | NEULAND LABORATORIES LTD. (IN) | 2006-05-11 | — | — | WO | disclosed |
| EP-0154780-B1 | QUINOLINE ANTIBACTERIAL COMPOUNDS | ABBOTT LABORATORIES (US) | 1990-04-11 | — | — | EP | disclosed |
| EP-0154780-A1 | Quinoline antibacterial compounds | ABBOTT LABORATORIES (US) | 1985-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244318-A1 | Process for the Preparation of Levofloxacin Hemihydrate | RTF1, CYP2F1, CYP4F11 | ESR1 4027/4885PKM 3840/4885SMN1; SMN2 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.